A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

Also called NCT06692764

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
  • Fortrea Registry lists this organization as a collaborator
Registry
  • NCT NCT06692764
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06692764. Randomized; triple masking; primary purpose treatment. Start 2024-10-30 (actual); primary completion 2025-04-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
Acronym
AZD0780-ABPM
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Placebo
Intervention (Drug)
AZD0780
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Fortrea (class: industry)

Record details

Record id
cardio:ct-nct06692764
Content hash
5294e37b02c8eb7b98d8219976a292d06da5e97fbd0a88ee0c7b18126c0658b2